Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Shares Outstanding (Weighted Average) (2020 - 2026)

MoonLake Immunotherapeutics' Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $71.3 million for Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) rose 12.71% to $71.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $71.3 million through Mar 2026, up 12.71% year-over-year, with the annual reading at $64.5 million for FY2025, 2.53% up from the prior year.
  • Shares Outstanding (Weighted Average) came in at $71.3 million for Q1 2026, up from $64.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $71.3 million in Q1 2026 to a low of $5.0 million in Q1 2022.
  • The 5-year median for Shares Outstanding (Weighted Average) is $62.6 million (2024), against an average of $50.5 million.
  • Year-over-year, Shares Outstanding (Weighted Average) skyrocketed 679.11% in 2023 and then grew 0.63% in 2025.
  • MoonLake Immunotherapeutics' Shares Outstanding (Weighted Average) stood at $29.4 million in 2022, then soared by 67.3% to $49.1 million in 2023, then increased by 27.99% to $62.9 million in 2024, then increased by 2.53% to $64.5 million in 2025, then increased by 10.56% to $71.3 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Shares Outstanding (Weighted Average) are $71.3 million (Q1 2026), $64.5 million (Q4 2025), and $63.3 million (Q3 2025).